Insider Selling: Immunome (NASDAQ:IMNM) Director Sells 36,800 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) Director Philip Wagenheim sold 36,800 shares of the business’s stock in a transaction on Friday, March 20th. The stock was sold at an average price of $20.47, for a total value of $753,296.00. Following the transaction, the director directly owned 369,347 shares of the company’s stock, valued at $7,560,533.09. This trade represents a 9.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Philip Wagenheim also recently made the following trade(s):

• On Monday, March 23rd, Philip Wagenheim sold 28,200 shares of Immunome stock. The stock was sold at an average price of $20.65, for a total value of $582,330.00.

Immunome Price Performance

NASDAQ:IMNM traded up $0.74 during trading hours on Monday, hitting $20.75. The company’s stock had a trading volume of 1,220,647 shares, compared to its average volume of 1,315,932. Immunome, Inc. has a twelve month low of $5.15 and a twelve month high of $27.65. The stock has a fifty day simple moving average of $22.76 and a 200-day simple moving average of $18.64. The company has a market capitalization of $2.35 billion, a P/E ratio of -8.57 and a beta of 2.12.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Immunome had a negative return on equity of 57.61% and a negative net margin of 1,687.08%. On average, equities analysts predict that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Evercore upped their price objective on shares of Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Stephens decreased their target price on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. Leerink Partners set a $40.00 price target on shares of Immunome in a report on Monday, December 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Thursday, January 22nd. Finally, Truist Financial assumed coverage on Immunome in a report on Monday, December 1st. They set a “buy” rating and a $36.00 price objective on the stock. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $33.45.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in IMNM. T. Rowe Price Investment Management Inc. lifted its position in shares of Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after purchasing an additional 5,003,824 shares during the period. JPMorgan Chase & Co. increased its position in shares of Immunome by 8,659.2% during the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after buying an additional 2,823,144 shares during the period. Primecap Management Co. CA increased its position in shares of Immunome by 55.2% during the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after buying an additional 1,667,432 shares during the period. Balyasny Asset Management L.P. bought a new position in Immunome during the fourth quarter worth $30,710,000. Finally, Sofinnova Investments Inc. raised its stake in Immunome by 271.2% during the fourth quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock worth $34,765,000 after buying an additional 1,182,426 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.